AstraZeneca Calquence plus chemoimmunotherapy approved in EU for 1st-line mantle cell lymphoma Ruchika Sharma7 May 2025 12:30 PM ISTCambridge: AstraZeneca has announced that Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the...
Fixed duration Calquence based regimens recommended for EMA Committee for chronic lymphocytic leukaemia: AstraZenaca Ruchika Sharma30 April 2025 1:30 PM ISTAstraZeneca has announced that a fixed-duration regimen of Calquence (acalabrutinib) in combination with venetoclax, with or without...
USFDA approves AstraZeneca Calquence, bendamustine, rituximab combo for previously untreated mantle cell lymphoma Ruchika Sharma18 Jan 2025 1:30 PM ISTCambridge: AstraZeneca has announced that the Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) in combination with...
Astrazeneca Calquence granted priority review by USFDA for previously untreated mantle cell lymphoma Ruchika Sharma5 Oct 2024 2:30 PM ISTCambridge: AstraZeneca's supplemental New Drug Application (sNDA) for Calquence (acalabrutinib) has been accepted and granted Priority Review in...
AstraZeneca, BioInvent ink pact to evaluate BI-1206 in combo with rituximab, Calquence Ruchika Sharma12 Feb 2024 4:30 PM ISTSweden: BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory...
AstraZeneca Calquence approved in China for chronic lymphocytic leukaemia Ruchika Sharma5 Sept 2023 11:55 AM ISTCambridge: AstraZeneca’s Calquence (acalabrutinib), a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in...
AstraZeneca Calquence gets conditional nod in China for adults with previously treated mantle cell lymphoma Ruchika Sharma26 March 2023 10:00 AM ISTMantle cell lymphoma is a rare B-cell malignancy subtype and is typically clinically aggressive with a poor prognosis.
AstraZeneca Calquence tablet formulation approved in EU for adults with chronic lymphocytic leukaemia Ruchika Sharma23 Feb 2023 11:30 AM ISTCalquence (acalabrutinib) is a next-generation, selective inhibitor of Bruton's tyrosine kinase (BTK).
AstraZeneca Calquence gets Japenese nod for treatment-naïve chronic lymphocytic leukaemia Ruchika Sharma1 Jan 2023 10:00 AM ISTCalquence (acalabrutinib) is a next-generation, selective inhibitor of BTK.
GSK, Sanofi, Pfizer and other drugmakers plan to raise prices on at least 350 drugs in US in January Ruchika Sharma31 Dec 2022 1:15 PM ISTTo date, Pfizer announced the most increases, with prices rising on 89 unique drug brands, and an additional increase on 10 drug brands at its Hospira...
AstraZeneca gets CDSCO Panel nod to market anticancer drug Acalabrutinib Susmita Roy3 Dec 2022 6:00 PM ISTNew Delhi: In a significant development, granting the proposal presented by drug major AstraZeneca Pharma India, the Subject Expert Committee (SEC)...
AstraZeneca new tablet formulation of Calquence gets USFDA okay Ruchika Sharma8 Aug 2022 12:30 PM IST"The tablet can be taken with gastric acid-reducing agents, including proton pump inhibitors (PPIs), antacids and H2-receptor antagonists (H2RAs),"...
